← Back to Search

Monoclonal Antibodies

Tildrakizumab for Psoriasis

Phase 4
Recruiting
Led By Raymond Cho, MD, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Patients with moderate-severe psoriasis or > 5% body surface area affected.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months
Awards & highlights

Study Summary

This trial will study how well an experimental drug works in people with psoriasis.

Who is the study for?
This trial is for adults over 18 with moderate to severe psoriasis, affecting more than 5% of their body. It's not suitable for those on systemic immunosuppressives in the last month, pregnant or breastfeeding individuals, people with severe immune deficiencies, active tuberculosis or other serious infections, and anyone with an active systemic cancer.Check my eligibility
What is being tested?
The study is testing Tildrakizumab injections to see how they affect skin and blood immune cells in psoriasis patients. The goal is to understand the changes in immune function after starting treatment with this IL23 blocker.See study design
What are the potential side effects?
Tildrakizumab may cause side effects such as upper respiratory infections, headache, fatigue, injection site reactions like pain or swelling, and possibly allergic reactions. Long-term use might increase infection risk due to its effect on the immune system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My psoriasis is severe or covers more than 5% of my body.
Select...
My psoriasis covers more than 5% of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tildrakizumab treatmentExperimental Treatment1 Intervention
Biological/vaccine: tildrakizumab

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,505 Previous Clinical Trials
15,237,545 Total Patients Enrolled
Sun Pharmaceutical Industries LimitedIndustry Sponsor
64 Previous Clinical Trials
13,501 Total Patients Enrolled
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
90 Total Patients Enrolled

Media Library

Tildrakizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05390515 — Phase 4
Plaque Psoriasis Research Study Groups: Tildrakizumab treatment
Plaque Psoriasis Clinical Trial 2023: Tildrakizumab Highlights & Side Effects. Trial Name: NCT05390515 — Phase 4
Tildrakizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05390515 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still slots open for participants in this research effort?

"As documented on clinicaltrials.gov this trial is not presently recruiting candidates. The initial advertisement was published September 1st 2022, and the latest update was registered May 20th 2022. Although no longer looking for patients, there are 167 other medical trials that currently have openings available."

Answered by AI

Could I potentially qualify for participation in this investigation?

"This research is seeking 10 adults, aged 18-75 years old who are afflicted with psoriasis. To qualify as a participant, they must be of eligible age and possess moderate to severe symptoms affecting more than 5% of their body surface area."

Answered by AI

Has the Tildrakizumab Prefilled Syringe been given authorization by the FDA?

"Our team has evaluated that Tildrakizumab Prefilled Syringe is in its fourth phase of clinical trials, which indicates it is approved and given a score of 3 for safety."

Answered by AI

Is the age criterion for inclusion in this clinical trial limited to individuals under 50 years old?

"To be eligible for this trial, the patient must fall between a 18-75 year old age range. The research team has identified 31 studies that target patients under 18 and 142 focused on those over 65 years of age."

Answered by AI

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
3+
Recent research and studies
clinicaltrials.govStudy
Psoriatic Immune Response to Tildrakizumab
2022. "Psoriatic Immune Response to Tildrakizumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05390515.
All > Psoriasis > Plaque Psoriasis
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top